Summary
Medtronic plc reported a strong quarter, with net sales increasing by 3% year-over-year to $7.9 billion for the three months ended July 26, 2024. This growth was driven by solid performance across key segments, including Cardiovascular and Diabetes. Diluted earnings per share (EPS) saw a significant increase to $0.80 from $0.59 in the prior year period, reflecting improved profitability. The company generated robust operating cash flow of $986 million, underscoring its strong operational execution. Medtronic also continued to return capital to shareholders through dividends and share repurchases, demonstrating a commitment to shareholder value. The company's financial position remains strong, with ample liquidity to fund operations and strategic initiatives.
Financial Highlights
53 data points| Revenue | $7.92B |
| Cost of Revenue | $2.76B |
| Gross Profit | $5.15B |
| SG&A Expenses | $2.65B |
| Operating Income | $1.28B |
| Net Income | $1.05B |
| EPS (Basic) | $0.81 |
| EPS (Diluted) | $0.80 |
| Shares Outstanding (Basic) | 1.29B |
| Shares Outstanding (Diluted) | 1.30B |
Key Highlights
- 1Net sales grew 3% to $7.9 billion, driven by growth in key segments like Cardiovascular and Diabetes.
- 2Diluted earnings per share (EPS) increased to $0.80 from $0.59 in the prior year's comparable period.
- 3Operating cash flow improved to $986 million from $875 million year-over-year.
- 4The company repurchased approximately $2.5 billion in shares during the quarter, signaling confidence and commitment to returning value to shareholders.
- 5The Cardiovascular segment showed a 6% increase in net sales, bolstered by strong performance in Cardiac Rhythm & Heart Failure and Structural Heart & Aortic.
- 6The Diabetes segment reported a 12% increase in net sales, primarily due to the strong adoption of the MiniMed 780G insulin pump system in the U.S.
- 7Medtronic maintained a strong liquidity position with $1.3 billion in cash and cash equivalents and $6.5 billion in current investments.